

USSN: 10/040,281

- 2 -

Art Unit: 1635

In the Claims:

Please cancel claims 1-24, 26, and 28.

Please amend claims 25 and 27.

Please add new claims 29-38.

Claims 1-24. **Cancelled.**

25. **(Currently amended)** A method for ~~preventing~~, treating or lessening the advancement, severity, or effects of HIV infection, ~~neoplasia, inflammation or inflammatory diseases, or autoimmune disease~~, comprising administering an effective amount of a composition comprising a pharmaceutically acceptable carrier and a polypeptide selected from the group consisting of a polypeptide according to any one of claims 1-8, a polypeptide complex according to any one of claims 16-19,

(a) a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 2;

(b) a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 4;

(c) a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 6;

(d) a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 2

wherein the amino acids Leu Gly Leu at the amino terminus of said sequence are replaced by a single Met or Leu residue.

~~antibodies to any one of the above, or a combination of any of the above, and a pharmaceutically acceptable carrier.~~

26. **Cancelled.**

27. **(Currently amended)** A method for suppressing the immune system comprising administering an effective amount of a composition comprising a pharmaceutically acceptable carrier and a polypeptide selected from the group consisting of a polypeptide according to any one of claims 1-8, a polypeptide complex according to any one of claims 16-19,

(a) a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 2;

(b) a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 4;

(c) a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 6;

USSN: 10/040,281

- 3 -

Art Unit: 1635

(d) a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 2 wherein one or more amino acids from the sequence Leu Gly Leu at the amino terminus of said sequence are replaced by a single Met or Leu residue.
~~antibodies to any one of the above, or a combination of any of the above, and a pharmaceutically acceptable carrier.~~

28. **Cancelled.**

29. **(New)** A method for treating or lessening the advancement, severity, or effects of neoplasia, comprising administering an effective amount of a composition comprising a pharmaceutically acceptable carrier and a polypeptide selected from the group consisting of

- (a) a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 2;
- (b) a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 4;
- (c) a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 6;
- (d) a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 2

wherein the amino acids Leu Gly Leu at the amino terminus of said sequence are replaced by a single Met or Leu residue.

30. **(New)** A method for preventing, treating or lessening the advancement, severity, or effects of inflammation or inflammatory diseases, comprising administering an effective amount of a composition comprising a pharmaceutically acceptable carrier and a polypeptide selected from the group consisting of

- (a) a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 2;
- (b) a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 4;
- (c) a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 6;
- (d) a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 2

wherein the amino acids Leu Gly Leu at the amino terminus of said sequence are replaced by a single Met or Leu residue.

31. **(New)** A method for treating or lessening the advancement, severity, or effects of an autoimmune disease comprising administering an effective amount of a composition comprising a pharmaceutically acceptable carrier and a polypeptide selected from the group consisting of

- (a) a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 2;
- (b) a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 4;
- (c) a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 6;

USSN: 10/040,281

- 4 -

Art Unit: 1635

(d) a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 2 wherein the amino acids Leu Gly Leu at the amino terminus of said sequence are replaced by a single Met or Leu residue.

32. (New) The method of claim 31, wherein the autoimmune disease is insulin-dependent diabetes melitis or lupus erythematosus.

33. (New) A method for treating or lessening the advancement, severity, or effects of an autoimmune disease comprising administering an effective amount of a composition comprising a pharmaceutically acceptable carrier and a polypeptide complex comprising a first polypeptide selected from a group consisting of:

- (a) a polypeptide comprising an amino acid sequence comprising SEQ ID NO: 2;
 - (b) a polypeptide comprising an amino acid sequence comprising SEQ ID NO: 4;
 - (c) a polypeptide comprising an amino acid sequence comprising SEQ ID NO: 6;
 - (d) a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 2 wherein one or more amino acids from the sequence Leu Gly Leu at the amino terminus of said sequence are replaced by a single Met or Leu residue; and
- a second polypeptide which is lymphotoxin- α .

34. (New) The method of claim 33, wherein the autoimmune disease is insulin-dependent diabetes melitis or lupus erythematosus.

35. (New) A method for treating or lessening the advancement, severity, or effects of neoplasia, comprising administering an effective amount of a composition comprising a pharmaceutically acceptable carrier and an antibody directed to a polypeptide selected from the group consisting of

- (a) a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 2;
- (b) a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 4;
- (c) a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 6;
- (d) a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 2 wherein the amino acids Leu Gly Leu at the amino terminus of said sequence are replaced by a single Met or Leu residue.

USSN: 10/040,281

- 5 -

Art Unit: 1635

36. (New) A method for preventing, treating or lessening the advancement, severity, or effects of inflammation or inflammatory diseases, comprising administering an effective amount of a composition comprising a pharmaceutically acceptable carrier and an antibody directed to a polypeptide selected from the group consisting of

- (a) a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 2;
- (b) a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 4;
- (c) a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 6;
- (d) a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 2

wherein the amino acids Leu Gly Leu at the amino terminus of said sequence are replaced by a single Met or Leu residue.

37. (New) A method for treating or lessening the advancement, severity, or effects of an autoimmune disease comprising administering an effective amount of a composition comprising a pharmaceutically acceptable carrier and an antibody directed to a polypeptide selected from the group consisting of

- (a) a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 2;
- (b) a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 4;
- (c) a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 6;
- (d) a polypeptide comprising the amino acid sequence defined by SEQ ID NO: 2

wherein the amino acids Leu Gly Leu at the amino terminus of said sequence are replaced by a single Met or Leu residue.

38. (New) The method of claim 37, wherein the autoimmune disease is insulin-dependent diabetes melitis or lupus erythematosus.